News: The Latest
Press Releases
Bicara Therapeutics to Host Webinar to Review Latest Clinical Trial Data for BCA101
Bicara Therapeutics to Present Clinical Data from Lead Precision Tumor Modulator Program, BCA101, at ESMO Congress 2022
Contact Information
GENERAL
BUSINESS DEVELOPMENT
MEDIA
Chris Railey
chris@tenbridgecommunications.com
INVESTORS
Sarah McCabe
Sarah.McCabe@sternir.com
Presentations
Webinar: Clinical Update on BCA101: Overview and Discussion of Newly Presented Data
Bicara Webinar, September 2022
Video Presentation: Bicara Therapeutics Company Overview
Piper Sandler 33rd Annual Virtual Healthcare Conference, November 2021
Poster Presentation: Development of BCA101, a Bifunctional Antibody Capable of Simultaneously Disabling EGFR and TGF-β Signaling, as a Novel Single-agent Immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting, November 2021
Digital Presentations: First-in-human Phase I Study of the Bifunctional EGFR/TGFβ Fusion Protein BCA101 in Patients with EGFR-driven Advanced Solid Cancers
American Society of Clinical Oncology, June 2021